November 29, 2016 - By Richard Conner · 0 Comments
The stock of Chimerix Incorporated (NASDAQ:CMRX) registered an increase of 2.41% in short interest. CMRX’s total short interest was 4.08M shares in November as published by FINRA. Its up 2.41% from 3.98 million shares, reported previously. With 451,600 shares average volume, it will take short sellers 9 days to cover their CMRX’s short positions. The short interest to Chimerix Incorporated’s float is 11.33%. About 155,895 shares traded hands. Chimerix Inc (NASDAQ:CMRX) has declined 17.25% since April 26, 2016 and is downtrending. It has underperformed by 22.51% the S&P500.
Chimerix, Inc. is a biopharmaceutical company. The company has a market cap of $225.79 million. The Firm is focused on discovering, developing and commercializing oral antivirals. It currently has negative earnings. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.
Insitutional Activity: The institutional sentiment increased to 1.05 in 2016 Q2. Its up 0.25, from 0.8 in 2016Q1. The ratio is positive, as 23 funds sold all Chimerix Inc shares owned while 37 reduced positions. 16 funds bought stakes while 32 increased positions. They now own 30.87 million shares or 5.26% less from 32.59 million shares in 2016Q1.
Virginia Retirement Et Al accumulated 0% or 26,300 shares. Fred Alger Management holds 0% or 36,150 shares in its portfolio. The Delaware-based Blackrock Limited Liability Corporation has invested 0% in Chimerix Inc (NASDAQ:CMRX). Price T Rowe Associate Md has 160,298 shares for 0% of their US portfolio. Highbridge Lc has 0% invested in the company for 28,656 shares. The Connecticut-based Trexquant Invest Ltd Partnership has invested 0.04% in Chimerix Inc (NASDAQ:CMRX). Tower Research Cap Ltd Liability Company (Trc) reported 12,611 shares or 0% of all its holdings. Pub Employees Retirement Association Of Colorado has invested 0% of its portfolio in Chimerix Inc (NASDAQ:CMRX). Royal National Bank & Trust Of Canada holds 24,000 shares or 0% of its portfolio. Panagora Asset Management has 0.01% invested in the company for 467,870 shares. Numeric Investors Limited Liability Corp owns 2.07 million shares or 0.07% of their US portfolio. Los Angeles Capital & Equity Research Inc accumulated 81,945 shares or 0% of the stock. Teacher Retirement Systems Of Texas has invested 0% of its portfolio in Chimerix Inc (NASDAQ:CMRX). Nationwide Fund Advisors holds 0% of its portfolio in Chimerix Inc (NASDAQ:CMRX) for 30,079 shares. State Board Of Administration Of Florida Retirement Systems last reported 29,098 shares in the company.
Insider Transactions: Since August 29, 2016, the stock had 1 insider purchase, and 1 insider sale for $75,063 net activity. Berrey M Michelle also bought $100,226 worth of Chimerix Inc (NASDAQ:CMRX) shares. LEONARD JOHN M. sold $25,163 worth of stock or 5,000 shares.
Out of 7 analysts covering Chimerix Inc (NASDAQ:CMRX), 2 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 29% are positive. Chimerix Inc has been the topic of 16 analyst reports since August 5, 2015 according to StockzIntelligence Inc. FBR Capital initiated the shares of CMRX in a report on Tuesday, August 18 with “Outperform” rating. On Tuesday, December 29 the stock rating was downgraded by JP Morgan to “Neutral”. The company was maintained on Tuesday, December 29 by Barclays Capital. UBS initiated Chimerix Inc (NASDAQ:CMRX) on Thursday, December 17 with “Buy” rating. On Monday, December 28 the stock rating was maintained by Piper Jaffray with “Overweight”. As per Tuesday, February 23, the company rating was downgraded by Morgan Stanley. Citigroup initiated Chimerix Inc (NASDAQ:CMRX) on Thursday, September 3 with “Buy” rating. The rating was maintained by Brean Capital with “Buy” on Thursday, August 6. The stock has “Mkt Perform” rating given by FBR Capital on Monday, December 28. Barclays Capital downgraded it to “Equal-Weight” rating and $6 target price in Tuesday, February 23 report.
Chimerix, Inc. (Chimerix), incorporated on April 7, 2000, is a biopharmaceutical company. The Firm is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available.
More important recent Chimerix Inc (NASDAQ:CMRX) news were published by: Marketwatch.com which released: “Chimerix Inc. NASDAQ: CMRX” on April 13, 2013, also Quotes.Wsj.com published article titled: “Chimerix Inc. CMRX (US: Nasdaq)”, Fool.com published: “Here’s Why Chimerix Inc Jumped 14.3% in April” on May 06, 2016. More interesting news about Chimerix Inc (NASDAQ:CMRX) was released by: Fool.com and their article: “Why Chimerix Inc. Is Up Big Today” with publication date: January 19, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Richard Conner